



Ghada Araji,¹ Julian Maamari,¹ Fatima Ali Ahmad,¹ Rana Zareef,² Patrick Chaftari,³ Sai-Ching Jim Yeung³

¹LAU Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon; ²Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon;


³Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

INTRODUCTION

Immune checkpoint inhibitors (ICIs) target proteins involved in the inhibitory regulation of immune responses



The gut microbiome is an important regulator of systemic immune reactions



STUDY QUESTION



Does the gut microbiome play a key role in the cancer response to ICIs?

METHODOLOGY

Repository


Full-length publications screened and identified

Pubmed

Medline

Embase



RESULTS



Akkermansia, Ruminococcaceae, Faecalibacterium, Bacteroides, and Bifidobacterium



Beneficial therapeutic interventions



CONCLUSION



Gut microbiome diversity influences the clinical response to ICIs



Antibiotic-related dysbiosis adversely affects ICI efficacy

